Natco Pharma said it plans to utilize the cash flows generated by the launch of generic versions of Israel-based Teva’s top selling multiple sclerosis Copaxone 20 mg/ml and 40 mg/ml by its partner Mylan in US towards strengthening balance sheet and investing on business expansion.

Market size for Natco's Sorafenib drug is sub $100 mn: Religare

While the Sorafenib drug is not a big opportunity for Natco, approval from Kothur plant is a big positive, says Praful Bohra of Religare Capital Markets.

Indian pharma cos need to step-up safeguards at plants: Handa

In the last five months, plants of nine Indian pharmaceutical companies - Cipla, Dr Reddy‘s, Sun Pharma, Cadila, Lupin and Natco Pharma.- have come under the US Food and Drug Administration (FDA) scanner.

USFDA observations won't hit Natco product launches: Nirmal Bang

Sumit Singhania of Nirmal Bang says that the observations are minor and can be resolved easily.

Sub-license for Hepatitis C drug beneficial for patients: Cipla

Jaideep Gogtay, Clinical Head at Cipla pointed out that in India the cost of treatment of Hepatitis C ranges between Rs 75,000 to Rs 1.5 lakh per patient, depending on the type of virus and the intensity.

Won license to make one of Bayers product: Natco's CFO

In an interview with CNBC-TV18, Bhaskar Narayana, finance director & CFO of Natco Pharma spoke about the judgment where the company is granted compulsory license to manufacture one of the Bayer’s products. He also talks about the market size of the drug and the amount of royalty to be paid.

See good boost in revenues in FY13: Natco Pharma

In an interview to CNBC-TV18, Bhaskar Narayana, chief financial officer of Natco Pharma says, FY13 should see atleast one abbreviated new drug application (ANDA) coming through. “FY13 would be a very exciting year for the company because it should result in good boost to the revenues,” he adds.

QIP of Rs 100cr to result in 7-8% dilution: Natco Pharma

Some agencies have been reporting that Natco Pharma’s fund raising plan might be expedited and take place in the next one or two months. Finance director and chief financial officer Bhaskar Narayana told CNBC-TV18 that the Rs 100 crore qualified institutional placement (QIP) would result in 7-8% dilution.

Will make, sell products in bio-generic space: Natco Pharma

In an interview with CNBC-TV18, Bhaskar Narayana, Finance Director & CFO of Natco Pharma talks about the pact with the Swiss based company and its impact on the company’s revenues going forward.

Natco Pharma may sell US-based pharmacy store SaveMart

In an interview on CNBC-TV18, Bhaskar Narayana, finance director and chief financial officer at Natco Pharma said that synergies with the SaveMart Pharmacy exist no longer.

Gilead, Roche's suit on expected lines: Natco Pharma

In an interview with CNBC-TV18, Bhaskar Narayana, Finance Director & CFO, Natco Pharma said," In a patently challenged issue, the innovator is bound to protect his rights and this can be done only through the mechanism of suing.There is nothing extra-ordinary about it."

Natco Pharma eyes 9-10% revenue growth in FY11

In an interview with CNBC-TV18, Bhaskar Narayana, Finance Director and CFO, Natco Pharma, speaks about the results and gives his outlook going forward.

At-risk launch likely for Tamiflu generic: Natco Pharma

In an interview with CNBC-TV18, Bhaskar Narayana, Finance Director & CFO, Natco Pharma gave his perspective on the tie-up with Alvogen and the first-to-file opportunity for Tamiflu.

Expect to cross Rs 500cr in revenue this yr: Natco Pharma

Hyderabad-based Natco Pharma has sought permission from drug major Pfizer to sell discounted copies of its HIV drug. In an interview with CNBC-TV18, Bhaskar Narayana, Finance Director & CFO, Natco Pharma threw light on the development and spoke on the company's business plans going forward.